S. Gail Eckhardt named to key roles in experimental therapeutics, translational research at Baylor

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Unexpected role of OTX2 drives aggressive medulloblastoma

Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Pan-cancer proteogenomics reveals potential drug targets

Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets.

June 28, 2024

Vol.50 No.26

Clinical Roundup

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

May 31, 2024

Vol.50 No.22